Levin’s Legacy: Teva’s Alternative Development Program
Research - CEO Jeremy Levin may be gone from Teva (TEVA), but it’s clear that while his tenure was short, his legacy may be meaningful. The challenge … Continue Reading
Read nowAuthor Archives: Beth Senko, CFA
Lexicon’s Pipeline Continues to Struggle
Insights - Lexicon Pharmaceuticals (LXRX) announced the latest in a string of disappointments for its development pipeline, but management remains upbeat. On December 3, 2013, the company … Continue Reading
Read now
OncoMed Shares Soar on Celgene Agreement
Insights - OncoMed (OMED) rose nearly 100% to $27.70 per share on December 3, 2013, when it announced that an agreement with Celgene (CELG) to co-develop and … Continue Reading
Read now
Baxter and Halozyme resubmit HyQvia to FDA
Insights - If at first you don’t succeed, try again. Baxter Healthcare (BAX) and Halozyme Therapeutics, Inc. (HALO) submitted an amended biologics license application (BLA) to the … Continue Reading
Read now
Idenix Sues Gilead for Hep-C Patent Infringement
Insights - The turf battle for the lucrative Hepatitis-C market is heating up, not only on the clinical front but also in the courts. Idenix Pharmaceuticals, Inc. … Continue Reading
Read now
Merrimack’s MM-121 Misses Primary Endpoint in Phase 2 Study
Insights - Merrimack Pharmaceuticals’ (MACK) MM-121 failed to meet its primary endpoint in a study for the treatment of women with ER/PR+, HER2 negative metastatic breast cancer … Continue Reading
Read now
Threshold Pharmaceuticals’ Early Data on TH-302 for Glioblastoma
Insights - Threshold Pharmaceuticals (THLD) on Friday announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 … Continue Reading
Read now